ProCE Banner Activity

CE

The Evolving Management of Relapsed/Refractory Myeloma: Clinical, Economic, and Patient-Centric Strategies for Managed Care Pharmacy Professionals

Multimedia
In this on-demand webcast of a live symposium, expert faculty discuss the management of relapsed/refractory multiple myeloma, including considerations for managed care professionals.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: June 15, 2022

Expiration: June 14, 2023

No longer available for credit.

Share

Faculty

Rebecca Gonzalez

Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Bhavesh Shah

Bhavesh Shah, R.Ph, BCOP

Chief Pharmacy Officer
Hematology/Oncology and Specialty Pharmacy
Boston Medical Center Health System
Boston, Massachusetts

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Karyopharm Therapeutics Inc.

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with relapsed/refractory multiple myeloma as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recognize approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to aid the interprofessional, collaborative care team in treatment decision making using available data and patient-related and disease-related factors
  • Develop an understanding of the mechanisms of action of and clinical trial findings with recently FDA-approved novel therapies to facilitate optimal integration into treatment algorithms/clinical pathways
  • Assist the interprofessional, collaborative care team in the supportive care of patients with relapsed/refractory multiple myeloma through early detection and management of treatment-related adverse events
  • Identify ways managed care pharmacists can promote optimal clinical integration of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to reduce associated costs, decrease hospitalization, and improve outcomes for patients

Faculty Disclosure

Primary Author

Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Rebecca Gonzalez, PharmD, BCOP, has no relevant conflicts of interest to disclose.

Bhavesh Shah, R.Ph, BCOP

Chief Pharmacy Officer
Hematology/Oncology and Specialty Pharmacy
Boston Medical Center Health System
Boston, Massachusetts

Bhavesh Shah, RPh, BCOP, has disclosed that he has received funds for research support and consulting fees from Fujifilm, Incyte, Janssen, Novartis, Pfizer Rigel, and Sanofi.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Brian Purves, PharmD, MBA

Brian Purves has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Jamie Sebaaly,

Director, Educational Strategy

Jamielynn Sebaaly, PharmD, BCPS, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-095-H01-P has been assigned to this home study, application-based activity (initial release date 3-31-2022). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 15, 2022, through June 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with relapsed/refractory multiple myeloma.